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mately 3400 cases in the study. Age (<65>), sex, urgency
of admission and four co-morbidities were selected a
priori for sub-group analyses; diabetes mellitus, acute MI,
renal failure and dysrhythmia. Charges were converted to
costs using the U.S. CMS cost-to-charge ratio of 0.3574.
Economic data and the rates of clinical outcomes were
drawn from the Center’s patient-level data. Multi-factor
regressions were conducted to determine the incremental
effects of the four co-morbidities. Statistical signiﬁcance
and conﬁdence intervals were calculated for each 
endpoint. 
RESULTS: Average costs from admit to discharge were
$7,642 in total and pharmacy was $525 (p value <.05).
The geometric mean outcome rates were: death 0.8%,
2nd MI following PTCA 2.4%, revascularization proce-
dures 3.2%, hemorrhage 8.7%, transfusion 3.4% and
thrombocytopenia 1.3%. The sub-group with the highest
costs and worst clinical outcomes were women, urgently
admitted, > 65 years old who had renal failure, acute MI,
or dysrhythmia, in descending impact. 
CONCLUSION: The analyses provide a baseline to assess
the future impact of a new medication on the formulary,
as well as a basis to evaluate a new business agreement.
The economic and clinical analyses will be repeated 
following the new medication’s usage, and will then be
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OBJECTIVES: Capecitabine-docetaxel (CD) combina-
tion therapy signiﬁcantly prolongs time to disease 
progression and overall survival, compared with 
docetaxel monotherapy (D). This study assessed the 
cost-effectiveness of CD versus D from perspective of 
a US health delivery organization. 
METHODS: The model is based on analyses of a 
2-armed, balanced, multicenter, randomized trial of 
CD compared with D for the treatment of advanced
anthracycline-pretreated breast cancer (n = 511). Mean
time to progression and mean survival were estimated
using Kaplan-Meier methods. Data were collected on hos-
pital resource use data, infusions, drug use, and number
of consultations. Adjustments for QoL and cost per unit
of resources were based on published data. The uncer-
tainty in the cost-effectiveness was estimated using Monte
Carlo simulation methods. 
RESULTS: CD resulted in longer mean duration of 
treatment (129 days) than D (98 days). Patients lived an
average of 80 days longer with CD and experienced 64
days longer progression-free survival. No signiﬁcant 
differences were observed in medication use and con-
sultations. Patients receiving CD had fewer treatment-
related hospitalization days (4.8 days versus 5.5 days per
patient). Because of the lower planned docetaxel dose in
the combination arm (75 vs. 100mg/m2), the cumulative
dose of docetaxel was 648mg in combination, compared
with 847mg in monotherapy. 93% of the acquisition cost
of capecitabine was offset by lower docetaxel costs for
total added costs of $1,341. Cost per quality-adjusted
year of life (QALY) gained with CD was $5,520. The 5th
and 95th percentiles of cost-effectiveness were $4,400
and $11,600, respectively. 
CONCLUSIONS: Combining capecitabine with doc-
etaxel is cost-effective compared with docetaxel
monotherapy in anthracycline-pretreated patients, by CD
signiﬁcantly prolonging time to progression and overall
survival and lowering treatment-related hospitalization
days. The results of the simulation analyses provide 
assurance that combination therapy is likely to be cost-
effective when applied to non-trial settings.
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OBJECTIVES: We performed a pharmacoeconomic 
evaluation of LHRH agonists (LAs) in treating metasta-
tic prostate cancer compared to standard care, as identi-
ﬁed in the literature and by clinical experts, including:
estrogens (DES), orchiectomy, antiandrogens (AAs), and
combinations therapy (LAs + AAs). 
METHODS: A Markov model was constructed to
perform a cost-utility analysis (CUA) over 5 years, from
a Canadian provincial healthcare payer perspective.
Treatment efﬁcacy was determined by meta-analysis of
published clinical data, and utilities were derived from the
literature. 
RESULTS: In the base case analysis, DES was least costly
($588) but also least effective (0.52 QALYs). Orchiec-
tomy ($830 for 0.92 QALYs), with an incremental 
cost-utility ratio of $615/QALY versus DES, dominated
LAs ($8,116 for 0.75 QALYs) and AAs ($4,108 for 
0.62 QALYs). Treatment with combination therapy was 
the most costly at $18,029 and the most effective 
(1.04 QALYs), with an expected incremental ratio
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$141,220/QALY versus orchiectomy. Changes in key
variables in the sensitivity analyses did not affect the
ranking of the treatment strategies, suggesting that the
model was robust. 
CONCLUSIONS: LAs were dominated by orchiectomy
in the base case analysis and most sensitivity analyses.
Combination therapy displayed incremental cost 
effectiveness ratios over orchiectomy ranging from
approximately $30,000 to over $100,000 per QALY.
Orchiectomy was more effective, had fewer severe
adverse reactions, and cost slightly more than DES, the
least expensive treatment. However, due to potential 
psychological impact, further research is warranted to
examine its acceptance by patients. Despite robustness,
the utilities used in the model warrant further research.
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OBJECTIVE: This study aimed to 1) assess and compare
the preferences and utilities for prostate cancer (PC)
health states from men at increased risk for disease to
published reports of healthy men, men with PC, and
physician preferences/utilities, and 2) evaluate the theo-
retical congruence of utility values solicited from an 
at-risk population with the conceptual framework for
utility elicitation, Welfare Economics. Several cost-utility
studies have shown little beneﬁt for the cost of screening
or treatment of asymptomatic PC. However, subjects
from whom utilities were elicited in these studies were not
those who would be most affected by health policy 
decisions. Further, several reports assessed utilities from
subjects who violate certain tenets (e.g., Veil of Ignorance)
of Welfare Economics. 
METHODS: 81 men without PC but at increased risk 
for disease (deﬁned by age, ethnicity and family history),
participating in a PC Risk Assessment Program, were
interviewed using the Time Trade-Off Technique. Men’s
preferences and utilities for health states of impotence and
incontinence associated with treatment options of PC
were assessed. 
RESULTS: Utility values ranged from a high of 0.8859
(SD 0.2317) for a small (10%) risk of incontinence 
associated with radiotherapy to a low of 0.7571 (SD
0.2802) for a high (99%) risk of impotence associated
with hormones. As compared to previous reports of
healthy men and physicians, men at-risk for PC in this
study had a higher utility for therapies that have a higher
probability of preserving quality of life, but not as high
as men diagnosed with PC. 
CONCLUSION: Men at-risk for PC had utilities values
for health states associated with treatment options 
intermediate between healthy men and men with cancer,
supporting our hypothesis. We discuss why populations
at-risk may theoretically be more congruent with Welfare
Economics and the Veil of Ignorance concept than 
populations previously reported in the literature.
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OBJECTIVE: To determine if cancer treatment choices
differ for prostate cancer patients who have had other
prior cancers versus those with no history of cancer. 
METHODS: Study was conducted using IMS HEALTH’s
LifeLink database, a U.S. employer claims database con-
sisting of more than 1.8 million covered lives, with linked
medical and pharmacy claims for employees, dependents,
and retirees from 1991 forward. Patients selected for the
study were newly diagnosed with primary prostate cancer
between during 1996–1997 and had at least one claim for
a therapy of interest (drug, surgery, or radiation) follow-
ing their cancer diagnosis. Differentiation of prostate
cancer patients with prior cancers and those without was
based on the documentation of any cancer diagnoses 
in the 36 months preceding their initial prostate cancer
diagnosis. Patients were observed for 36 months after
their diagnosis. 
RESULTS: 5,569 patients met the inclusion criteria of
which 2,811 had a history of prior cancer diagnoses, and
2,758 had no history of prior cancers. Prostate cancer
patients with prior cancers were signiﬁcantly more likely
to receive chemotherapy than patients without prior
cancers (p = 0.015) but were less likely to receive surgery
than patients without prior cancers (p = 0.011). Among
patients treated with chemotherapy, those with prior
cancers were more likely to receive ﬂuorouracil (p =
0.001), whereas patients with no prior cancers were more
likely to receive methotrexate (p = 0.002). Initial treat-
ment modalities also differed signiﬁcantly (p < 0.001),
with prior cancer patients more likely to initially receive
chemotherapy than patients without prior cancers 
(p < 0.001) and signiﬁcant differences in initial hormonal
therapies prescribed (p = 0.024). Among patients with
initial hormone therapy, those with prior cancers were
more likely to initially receive dexamethasone (p < 0.001). 
CONCLUSIONS: Treatment of prostate cancer differs
based on patient’s history of other cancers, both in type
of treatment received (drug, surgery, or radiation) and
selection of hormonal and chemotherapy regimens.
